

Freedom of Information Request: 0325 2019/20

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

I have a Freedom of Information request about Cancer treatments with your organisation.

Queen Elizabeth Hospital Birmingham:

- 1. How many melanoma patients undergoing treatment are BRAF+ ? We do not hold this information**
 - a. -In the past 3 months, how many melanoma patients were treated with the following:**
 - Bevacizumab - 0**
 - Cobimetinib - 0**
 - Dabrafenib - 0**
 - Dabrafenib AND trametinib - 0**
 - Dacarbazine - 0**
 - Encorafenib AND binimetinib - 0**
 - Ipilimumab - 0**
 - Ipilimumab AND Nivolumab - 6**
 - Nivolumab - 1**
 - Pembrolizumab - 3**
 - Trametinib - 0**
 - Vemurafenib - 0**
 - Vemurafenib AND Cobimetinib - 0**
 - Other active systemic anti-cancer therapy - 0**
 - Palliative care - 0**
 - b. In the past 3 months how many patients were seen who had stage III resectable melanoma? 3**
 - c. Of all stage III patients seen, how many received a complete resection? 2**
 - d. Of all stage III patients seen, how many were stage III a? - 1**
- 2. In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:**
 - Afatinib – 0**

Atezolizumab monotherapy - 0

Bevacizumab – 0

Docetaxel monotherapy - 0

Durvalumab - 0

Erlotinib - 0

Gemcitabine - 5

Necitumumab - 0

Nivolumab - 0

Paclitaxel b

Pembrolizumab monotherapy - 0

Pembrolizumab chemo in combination - 0

Pemetrexed - 0

Ramucirumab - 0

Vinorelbine and cisplatin / carboplatin - 1

Other active systemic anti-cancer therapy [please state] - 0

Palliative care only - 1

3. In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:

Afatinib - 2

Alectinib - 0

Atezolizumab mono - 0

Atezolizumab + bevacizumab + carboplatin + paclitaxel - 0

Bevacizumab - 0

Brigatinib - 0

Ceritinib - 0

Crizotinib - 0

Dacomitinib - 0

Docetaxel monotherapy - 0

Erlotinib - 0

Gefitinib - 0

Nintedanib with docetaxel - 0

Nivolumab - 0

Osimertinib - 0

Paclitaxel - 0

Pembrolizumab monotherapy - 1

Pembrolizumab chemo in combination - 7

Pemetrexed with carboplatin - 2

Pemetrexed with cisplatin - 1

Ramucirumab - 0

Other active systemic anti-cancer therapy [please state]

Cisplatin and oral Vinorelbine - 1

Etoposide & Carboplatin (limited stage) - 1

Palliative care only - 4

4. In the past 3 months, how many Urothelial cancer patients were treated with;

Atezolizumab - 0

Carboplatinum in combination with another agent - 0

Carboplatinum single agent - 0

Cisplatinum in combination with another agent - Gemcitabine & Cisplatin (Fractionated) (\pm Zoledronic acid) - 3

Cisplatinum single agent - 0

Nivolumab - 0

Pembrolizumab – 0

Any other chemo regimen without cisplatinum or carboplatinum - 0

Other active systemic anti-cancer therapy [please state] - 0

Palliative care only - 1

Heartlands, Good Hope and Solihull Hospitals:

1. How many melanoma patients undergoing treatment are BRAF+ ? Not Applicable

a. -In the past 3 months, how many melanoma patients were treated with the following:

Bevacizumab - 0

Cobimetinib - 0

Dabrafenib - 0

Dabrafenib AND trametinib - 0

Dacarbazine - 0

Encorafenib AND binimetinib - 0

Ipilimumab - 0

Ipilimumab AND Nivolumab - 0

Nivolumab - 0

Pembrolizumab - 0

Trametinib - 0

Vemurafenib - 0

Vemurafenib AND Cobimetinib - 0

Other active systemic anti-cancer therapy - 0

Palliative care - 0

b. In the past 3 months how many patients were seen who had stage III resectable melanoma? Not Applicable

c. Of all stage III patients seen, how many received a complete resection? Not Applicable

d. Of all stage III patients seen, how many were stage III a? - NA

2. In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:

Afatinib – 9 (total number)

Atezolizumab monotherapy – 13 (total number)

Bevacizumab – 0

Docetaxel monotherapy – 2 (total number)

Durvalumab – 4 (total number)

Erlotinib – 2 (total number)

Gemcitabine – 2 (total number)

Necitumumab - 0

Nivolumab – 1 (total number)

Paclitaxel - 0

Pembrolizumab monotherapy – 24 (total number)

Pembrolizumab chemo in combination – 12 (total number)

Pemetrexed – 3 (total number)

Ramucirumab - 0

Vinorelbine and cisplatin / carboplatin – 1 (total number)

Other active systemic anti-cancer therapy [please state] – Unable to answer.

Palliative care only – Unable to answer.

3. In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:

Afatinib – 9 (total number)

Alectinib – 8 (total number)

Atezolizumab mono – 13 (total number)

Atezolizumab + bevacizumab + carboplatin + paclitaxel – 1 (total number)

Bevacizumab - 0

Brigatinib - 0

Ceritinib – 2 (total number)

Crizotinib - 0

Dacomitinib – 9 (total number)

Docetaxel monotherapy – 2 (total number)

Erlotinib – 2 (total number)

Gefitinib – 5 (total number)

Nintedanib with docetaxel – 1 (total number)

Nivolumab – 1 (total number)

Osimertinib – 6 (total number)

Paclitaxel - 0

Pembrolizumab monotherapy – 24 (total number)

Pembrolizumab chemo in combination – 12 (total number)

Pemetrexed with carboplatin – 3 (total number)

Pemetrexed with cisplatin – 7 (total number)

Ramucirumab - 0

Other active systemic anti-cancer therapy [please state] Unable to answer

Palliative care only – Unable to answer

4. In the past 3 months, how many Urothelial cancer patients were treated with;

Atezolizumab - 0

Carboplatinum in combination with another agent – 1 (total number)

Carboplatinum single agent - 0

Cisplatinum in combination with another agent – 7 (total number)

Cisplatinum single agent - 0

Nivolumab - 0

Pembrolizumab – 9

Any other chemo regimen without cisplatinum or carboplatinum - 4

Other active systemic anti-cancer therapy [please state] – Unable to answer

Palliative care only – Unable to answer

Please note that the figures are total numbers of patients, as we are unable to determine histology from pharmacy records.